FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3038183229> ?p ?o ?g. }

• W3038183229 endingPage "907" @default.
• W3038183229 startingPage "900" @default.
• W3038183229 abstract "Background The LIR!C trial showed that laparoscopic ileocaecal resection is a cost-effective treatment that has similar quality-of-life outcomes to treatment with infliximab, an anti-tumour necrosis factor (TNF) drug. We aimed to compare long-term outcomes of both interventions and identify baseline factors associated with the duration of treatment effect in each group. Methods In this retrospective follow-up study, we collected data from patients who participated in the LIR!C trial, a multicentre randomised controlled trial that compared quality of life after surgical resection versus infliximab in adult patients with non-stricturing and immunomodulator-refractory ileocaecal Crohn's disease. From Jan 1 to May 1, 2018, we collected follow-up data from the time from enrolment in the LIR!C trial until the last visit at either the gastrointestinal surgeon or gastroenterologist. In this study, outcomes of interest were need for surgery or repeat surgery or anti-TNF therapy, duration of treatment effect, and identification of factors associated with the duration of treatment effect. Duration of treatment effect was defined as the time without need for additional Crohn's disease-related treatment (corticosteroids, immunomodulators, biologics, or surgery). Findings We collected long-term follow-up data for 134 (94%) of 143 patients included in the LIR!C trial, of whom 69 were in the resection group and 65 were in the infliximab group. Median follow-up was 63·5 months (IQR 39·0–94·5). In the resection group, 18 (26%) of 69 patients started anti-TNF therapy and none required a second resection. 29 (42%) patients in the resection group did not require additional Crohn's disease-related medication, although 14 (48%) of these patients were given prophylactic immunomodulator therapy. In the infliximab group, 31 (48%) of 65 patients had a Crohn's disease-related resection, and the remaining 34 patients maintained, switched, or escalated their anti-TNF therapy. Duration of treatment effect was similar in both groups, with a median time without additional Crohn's disease-related treatment of 33·0 months (95% CI 15·1–50·9) in the resection group and 34·0 months (0·0–69·3) in the infliximab group (log-rank p=0·52). In both groups, therapy with an immunomodulator, in addition to the allocated treatment, was associated with duration of treatment effect (hazard ratio for resection group 0·34 [95% CI 0·16–0·69] and for infliximab group 0·49 [0·26–0·93]). Interpretation These findings further support laparoscopic ileocaecal resection as a treatment option in patients with Crohn's disease with limited (affected segment ≤40 cm) and predominantly inflammatory terminal ileitis for whom conventional treatment is not successful. Funding None." @default.
• W3038183229 created "2020-07-10" @default.
• W3038183229 creator A5007361135 @default.
• W3038183229 creator A5007945798 @default.
• W3038183229 creator A5008855604 @default.
• W3038183229 creator A5009083184 @default.
• W3038183229 creator A5009248924 @default.
• W3038183229 creator A5011613312 @default.
• W3038183229 creator A5011860225 @default.
• W3038183229 creator A5016313024 @default.
• W3038183229 creator A5016527077 @default.
• W3038183229 creator A5017199812 @default.
• W3038183229 creator A5017993724 @default.
• W3038183229 creator A5020683495 @default.
• W3038183229 creator A5021806501 @default.
• W3038183229 creator A5023376179 @default.
• W3038183229 creator A5023497327 @default.
• W3038183229 creator A5024571671 @default.
• W3038183229 creator A5026348627 @default.
• W3038183229 creator A5026935286 @default.
• W3038183229 creator A5029907141 @default.
• W3038183229 creator A5030608130 @default.
• W3038183229 creator A5031847439 @default.
• W3038183229 creator A5033279901 @default.
• W3038183229 creator A5035026075 @default.
• W3038183229 creator A5040981628 @default.
• W3038183229 creator A5041032137 @default.
• W3038183229 creator A5042501752 @default.
• W3038183229 creator A5046588150 @default.
• W3038183229 creator A5046592864 @default.
• W3038183229 creator A5046884577 @default.
• W3038183229 creator A5046932334 @default.
• W3038183229 creator A5048047845 @default.
• W3038183229 creator A5048322247 @default.
• W3038183229 creator A5048480234 @default.
• W3038183229 creator A5048918402 @default.
• W3038183229 creator A5049110948 @default.
• W3038183229 creator A5049969785 @default.
• W3038183229 creator A5050614817 @default.
• W3038183229 creator A5050621572 @default.
• W3038183229 creator A5052219587 @default.
• W3038183229 creator A5053786012 @default.
• W3038183229 creator A5054051358 @default.
• W3038183229 creator A5054201171 @default.
• W3038183229 creator A5056187637 @default.
• W3038183229 creator A5057018386 @default.
• W3038183229 creator A5057841250 @default.
• W3038183229 creator A5057899912 @default.
• W3038183229 creator A5059137554 @default.
• W3038183229 creator A5064326605 @default.
• W3038183229 creator A5066016182 @default.
• W3038183229 creator A5066763148 @default.
• W3038183229 creator A5067351502 @default.
• W3038183229 creator A5068540938 @default.
• W3038183229 creator A5068944242 @default.
• W3038183229 creator A5075556733 @default.
• W3038183229 creator A5076509716 @default.
• W3038183229 creator A5077573226 @default.
• W3038183229 creator A5078561640 @default.
• W3038183229 creator A5080164733 @default.
• W3038183229 creator A5081602075 @default.
• W3038183229 creator A5081690335 @default.
• W3038183229 creator A5082287042 @default.
• W3038183229 creator A5085249069 @default.
• W3038183229 creator A5085711650 @default.
• W3038183229 creator A5086705434 @default.
• W3038183229 creator A5088723020 @default.
• W3038183229 creator A5088779224 @default.
• W3038183229 creator A5090509187 @default.
• W3038183229 creator A5091203771 @default.
• W3038183229 date "2020-10-01" @default.
• W3038183229 modified "2023-10-17" @default.
• W3038183229 title "Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial" @default.
• W3038183229 cites W1607808246 @default.
• W3038183229 cites W1671682816 @default.
• W3038183229 cites W1966893199 @default.
• W3038183229 cites W1979115919 @default.
• W3038183229 cites W1979236956 @default.
• W3038183229 cites W1981704297 @default.
• W3038183229 cites W2059357675 @default.
• W3038183229 cites W2086096279 @default.
• W3038183229 cites W2122527047 @default.
• W3038183229 cites W2126807394 @default.
• W3038183229 cites W2149170290 @default.
• W3038183229 cites W2161685971 @default.
• W3038183229 cites W2413225393 @default.
• W3038183229 cites W2507888236 @default.
• W3038183229 cites W2523659127 @default.
• W3038183229 cites W2523706394 @default.
• W3038183229 cites W2606184163 @default.
• W3038183229 cites W2739381758 @default.
• W3038183229 cites W2745687892 @default.
• W3038183229 cites W2765952171 @default.
• W3038183229 cites W2899100906 @default.
• W3038183229 doi "https://doi.org/10.1016/s2468-1253(20)30117-5" @default.
• W3038183229 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32619413" @default.
• W3038183229 hasPublicationYear "2020" @default.
• W3038183229 type Work @default.

• next